Clene Inc (CLNN)

Clene Inc.'s stock price has increased significantly, by 173.42% over the last year. Key events include Q3 2025 financial results with EPS and revenue below consensus estimates, strong analyst sentiment and price targets, participation in investor conferences, planned NDA submission for CNM-Au8 in ALS, insider stock option grants, preclinical data for Parkinson's Disease, Q2 2025 results and cash runway extension, an equity distribution agreement with Canaccord, and a registered direct offering.

Information regarding specific demand seasonality for Clene, Inc.'s products and services is not readily available. As a clinical-stage biopharmaceutical company, its primary focus is on the development and regulatory approval of drug candidates like CNM-Au8. Therefore, traditional "demand seasonality" in the commercial sense for these drug candidates is not applicable at this stage. While Clene also markets dietary supplements, detailed information on their specific demand seasonality was not found.

Clene, Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology (CSN) therapeutics to improve mitochondrial health and protect neuronal function, primarily for neurodegenerative and demyelinating diseases. Their lead drug candidate, CNM-Au8, is being investigated in clinical trials for ALS, MS, and Parkinson's Disease. Clene also develops CNM-AgZn17 for infectious diseases and wound healing, CNM-ZnAg as a broad-spectrum antiviral and antibacterial agent, and markets dietary supplements like rMetx and KHC46.

Clene Inc. is headquartered in Salt Lake City, Utah, with R&D and manufacturing operations in North East, Maryland. The company collaborates with academic institutions and clinical sites across North America and Australia for research and clinical investigations.

Clene Inc. maintains a positive brand reputation, particularly within the investment community, due to the potential of its nanotechnology therapeutics. The company receives "Strong Buy" or "Very Bullish" ratings from analysts and participates in investor conferences. News headlines highlight positive analyst recommendations and clinical trial updates. Financial losses are understood within the context of its development phase.

Clene Inc.'s ownership is divided among insiders, institutional investors, and retail investors. A significant stake is held by insiders. Major institutional owners and shareholders include Scoggin Management Lp, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, Lunt Capital Management, Inc., Parsons Capital Management Inc/ri, FSMAX - Fidelity Extended Market Index Fund, Renaissance Technologies Llc, Marshall Wace, Llp, Morgan Stanley, Northern Trust Corp., and SBI Securities Co., Ltd.